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Abstract Recent studies have indicated that arginase,
which converts L-arginine into L-ornithine and urea, may
play an important role in the pathogenesis of various
pulmonary disorders. In asthma, chronic obstructive pul-
monary disease (COPD) and cystic fibrosis, increased
arginase activity in the airways may contribute to obstruc-
tion and hyperresponsiveness of the airways by inducing a
reduction in the production of bronchodilatory nitric oxide
(NO) that results from its competition with constitutive
(cNOS) and inducible (iNOS) NO synthases for their
common substrate. In addition, reduced L-arginine avail-
ability to iNOS induced by arginase may result in the
synthesis of both NO and the superoxide anion by this
enzyme, thereby enhancing the production of peroxynitrite,
which has procontractile and pro-inflammatory actions.
Increased synthesis of L-ornithine by arginase may also
contribute to airway remodelling in these diseases. L-
Ornithine is a precursor of polyamines and L-proline, and
these metabolic products may promote cell proliferation
and collagen production, respectively. Increased arginase
activity may also be involved in other fibrotic disorders of
the lung, including idiopathic pulmonary fibrosis. Finally,
through its action of inducing reduced levels of vasodilating
NO, increased arginase activity has been associated with
primary and secondary forms of pulmonary hypertension.
Drugs targeting the arginase pathway could have therapeu-
tic potential in these diseases.
Keywords Arginase.Asthma.Chronicobstructive
pulmonarydisease.Cysticfibrosis.Nitricoxide.
Pulmonaryhypertension
Introduction
Arginase, which converts L-arginine into L-ornithine and
urea, is a key enzyme of the urea cycle in the liver, but it is
also expressed in cells and tissues that lack a complete urea
cycle, including the lung. Arginase exists as two distinct
isoenzymes, arginase I and II, which are encoded by
different genes. Arginase I is a cytosolic enzyme and is
the predominant isoform in the liver, where it is highly
expressed (Jenkinson et al. 1996; Wu and Morris 1998).
Although low levels of arginase II have been detected in
liver as well (Klasen et al. 2001), this mitochondrial enzyme
is mainly expressed in extrahepatic tissue (Jenkinson et al.
1996; Wu and Morris 1998). In the airways, both arginase I
and II are constitutively expressed in bronchial epithelial
cells, endothelial cells, (myo)fibroblasts and alveolar macro-
phages (Klasen et al. 2001; Lindemann and Racke 2003;
Que et al. 1998), while arginase II is also expressed in
parenchymal epithelial cells (Que et al. 1998). A number of
studies have reported that arginase expression in airway
smooth muscle was below detection limit (e.g. Que et al.
1998), while other studies have indicated that either isoform
may be (conditionally) expressed in these cells (Bergeron et
al. 2007; Zuyderduyn et al. 2006).
One of the biological functions of extrahepatic arginase
may be regulation of the synthesis of nitric oxide (NO) by
means of competition with NO synthase (NOS) for the
common substrate, L-arginine (Fig. 1). In activated macro-
phages, for example, arginase activity limits the utilization
of L-arginine by inducible NOS (iNOS) and suppresses the
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et al. 1995; Wang et al. 1995). The activity of arginase,
however, is inhibited by Nw-hydroxy-L-arginine (NOHA),
an intermediate in the NO synthesis. This interaction
demonstrates the delicate balance between NOS and
arginase activity in the control of NO production (Boucher
et al. 1994; Daghigh et al. 1994). In addition, extrahepatic
arginase may be involved in tissue repair processes through
the synthesis of L-ornithine. Thus, L-ornithine is a precursor
of polyamines and L-proline, which are involved in cell
proliferation and collagen synthesis, respectively (Satriano
2004; Shearer et al. 1997; Wu and Morris 1998).
A functional role for constitutively expressed arginase in
the airways has been established in guinea pig tracheal
preparations using the specific arginase inhibitor Nw-
hydroxy-nor-L-arginine (nor-NOHA). Thus, nor-NOHA
decreased methacholine-induced airway constriction by
increasing the production of non-neural, presumably
epithelium-derived, bronchodilating NO (Meurs et al.
2000). Moreover, the arginase inhibitor increased NO-
mediated airway smooth muscle relaxation induced by
inhibitory nonadrenergic noncholinergic (iNANC) nerve
stimulation (Maarsingh et al. 2005). In both studies, the
effects of nor-NOHA were quantitatively similar to the
effects of exogenously applied L-arginine, thereby provid-
ing experimental evidence that arginase is involved in the
control of airway responsiveness through attenuation
of substrate availability to NOS (De Boer et al. 1999;
Maarsingh et al. 2005; Meurs et al. 2000).
Aberrant NO homeostasis as well as exaggerated tissue
repair are involved in various inflammatory airway diseases
associated with reduced lung function, airway hyperres-
ponsiveness (AHR) and/or airway remodelling, such as
allergic asthma (Meurs et al. 2003; Ricciardolo et al. 2004),
chronic obstructive pulmonary disease (COPD; Barnes et
al. 2003; Hogg 2004; Postma and Kerstjens 1998) and
cystic fibrosis (Hays et al. 2005; Hilliard et al. 2007;
Tiddens and De Jong 2007). In addition, reduced levels of
NO have also been observed in lungs of patients with
pulmonary arterial hypertension (PAH; Kaneko et al. 1998),
while dysregulated tissue repair and excessive fibrosis in
the lung interstitium are observed in patients with idiopath-
ic pulmonary fibrosis (Gross and Hunninghake 2001). This
review will address the potential role of arginase in the
pathophysiology of these diseases.
Allergic asthma
Role of NO in allergic asthma
Allergic asthma is a chronic inflammatory airways disease,
characterized by allergen-induced early and late bronchial
obstructive reactions and AHR to a variety of stimuli,
including allergens, chemical irritants, cold air and phar-
macological agents, such as histamine and methacholine
(Bousquet et al. 2000). The development of bronchial
obstructive reactions as well as of AHR is associated with
an infiltration and activation of inflammatory cells, partic-
ularly Th2 lymphocytes and eosinophils, in the airways
(Bousquet et al. 2000). The cause of AHR may be multi-
factorial, involving changes in both the neurogenic and
non-neurogenic control of airway smooth muscle function
as well as structural changes in the airways, such as
epithelial damage, mucosal swelling and airway remodel-
ling that is characterized by increased airway smooth
muscle mass, subepithelial fibrosis, hyperplasia of mucous
cells and angiogenesis (Bousquet et al. 2000). All of these
changes can be induced by a cascade of inflammatory
reactions involving various mediators, including NO
(Bousquet et al. 2000; Ricciardolo et al. 2004; Ricciardolo
2003).
Nitric oxide is produced by a family of NOS isoforms
that convert L-arginine into NO and L-citrulline using
oxygen and NADPH as cosubstrates (Moncada et al.
1989). Three NOS isozymes have been identified to date:
neuronal NOS (nNOS or NOS I), inducible NOS (iNOS or
NOS II) and endothelial NOS (eNOS or NOS III). In the
respiratory tract, nNOS and/or eNOS are constitutively
expressed in iNANC neurons (nNOS) and in epithelial
Fig. 1 L-Arginine metabolism catalysed by arginase and nitric oxide
synthase (NOS). L-Arginine is a substrate of both NOS, yielding nitric
oxide (NO)a n dL-citrulline, and arginase, which in turn produces L-
ornithine and urea. Arginase regulates the production of NO by
competing with NOS for their common substrate. On the other hand,
Nw-hydroxy-L-arginine (NOHA), an intermediate in the NO synthesis
catalysed by NOS, inhibits arginase activity. In addition, the arginase
product L-ornithine is the precursor of the polyamines putrescine,
spermidine and spermine and of L-proline. OAT Ornithine aminotrans-
ferase, ODC ornithine decarboxylase, P5C L-pyrroline-5-carboxylate, 1
pyrroline-5-carboxylate reductase, 2 spermidine synthase, 3 spermine
synthase
172 Naunyn-Schmiedberg’s Arch Pharmacol (2008) 378:171–184(nNOS and eNOS) and endothelial (eNOS) cells. These
constitutive NOS (cNOS) isoenzymes are primarily in-
volved in the neural and non-neural regulation of airway
and vascular smooth muscle tone via both cGMP-
dependent and-independent mechanisms (Ricciardolo et
al. 2004). In addition, eNOS-derived NO has been shown
to inhibit airway inflammationb ys u p p r e s s i n gt h ea c t i v a -
tion of NF-κB, thereby inhibiting both the expression of
iNOS and the production of inflammatory cytokines
(Cirino et al. 2003;C o o ke ta l .2003; Marshall and
Stamler 2001; Ten Broeke et al. 2006; Thomassen et al.
1997). A number of studies have demonstrated that an
impaired production of cNOS-derived bronchodilating NO
contributes to the development of AHR in allergic asthma,
both in animal models and in human asthma (De Boer et
al. 1996; Maarsingh et al. 2006; Mehta et al. 1997;
Ricciardolo et al. 1997, 2001;S a m be ta l .2001; Schuiling
et al. 1998b).
Inducible NOS is induced in the airways through the
action of pro-inflammatory cytokines, particularly those
found in inflammatory and epithelial cells (Asano et al.
1994; Barnes 1998; Hamid et al. 1993). Inducible NOS-
derived NO may be involved in the infiltration of
inflammatory cells (Schuiling et al. 1998a), mucosal
swelling (Kuo et al. 1992) and epithelial damage (Flak
and Goldman 1996; Schuiling et al. 1998a), but it may also
have a beneficial bronchodilating action (De Gouw et al.
1998; Schuiling et al. 1998a), indicating a dualistic role in
the airways. In contrast to cNOS, iNOS produces large
amounts of NO, which causes increased concentrations of
NO in the exhaled air of asthmatics (Kharitonov et al.
1994). In experimentally induced asthma, iNOS is induced
in the airways during the allergen-induced late asthmatic
reaction, similarly leading to increased levels of NO in the
exhaled air (Kharitonov et al. 1995a; Yan et al. 1995). In
asthmatics, increased nitrotyrosine staining in the airways
correlates well with iNOS expression, AHR and airway
inflammation, suggesting that not iNOS-derived NO itself
but, rather, its reaction with superoxide to the highly
reactive oxidant peroxynitrite may be an important factor
accounting for the detrimental effects of iNOS in the
airways (Saleh et al. 1998). Indeed, peroxynitrite has
procontractile and proinflammatory actions and is involved
in the development of AHR after the late asthmatic reaction
or after repeated allergen challenge (De Boer et al. 2001;
Muijsers et al. 2001; Sadeghi-Hashjin et al. 1996, 1998).
Arginase in animal models of allergic asthma
A study using a guinea pig model of allergic asthma and
ovalbumin-sensitized animals demonstrated that a deficien-
cy of NO underlies the development of AHR following the
allergen-induced early asthmatic reaction (De Boer et al.
1996; Schuiling et al. 1998b) and that this NO deficiency is
caused by a decreased availability of L-arginine to cNOS
(De Boer et al. 1999; Maarsingh et al. 2006; Meurs et al.
2002). Using airway preparations from the same animal
model, it was demonstrated that increased arginase activity
may be involved in the reduced L-arginine bioavailability
and AHR. Thus, arginase activity in the airways of
allergen-challenged guinea pigs was 3.5-fold increased
after the early asthmatic reaction as compared to unchal-
lenged animals, while incubation with the arginase inhibitor
nor-NOHA completely reversed the allergen-induced AHR
of perfused tracheal preparations from these animals by
restoring NO production (Meurs et al. 2002). L-Arginine
limitation induced by increased arginase activity also
appeared to underlie an impaired iNANC nerve-mediated
airway smooth muscle relaxation after the early asthmatic
reaction by inducing a deficiency of nNOS-derived NO
(Maarsingh et al. 2006). Collectively, these findings
indicate a key role for arginase in the development AHR
following the allergen-induced early asthmatic reaction by
inducing a deficiency of both neuronal and non-neuronal
NO (Fig. 2).
A second mechanism by which increased arginase
activity may contribute to AHR in allergic asthma is
through the stimulation of peroxynitrite formation. Studies
in macrophages have indicated that under conditions of low
L-arginine availability iNOS not only produces NO by its
oxygenase moiety, but also synthesizes superoxide anions
by its reductase moiety, leading to an efficient formation of
peroxynitrite (Xia et al. 1998). Increasing the L-arginine
concentration in these cells stimulates NO production, while
the formation of superoxide – and hence peroxynitrite – is
reduced (Xia and Zweier 1997). In perfused guinea pig
tracheal preparations obtained after the allergen-induced
late asthmatic reaction, the AHR to methacholine was
reduced by both the NOS inhibitor L-NAME and the
superoxide anion scavenger superoxide dismutase (SOD),
indicating the involvement of peroxynitrite in this process
(De Boer et al. 2001). Remarkably, the AHR was similarly
diminished by the arginase inhibitor nor-NOHA and by
exogenous L-arginine, which is highly suggestive of the
reduced L-arginine availability caused by increased arginase
activity being involved in the iNOS-induced production of
peroxynitrite and AHR (Maarsingh et al. 2004). This
mechanism was underscored by the observation that the
effect of nor-NOHA was fully reversed by L-NAME,
indicating that arginase inhibition restores the production
of bronchodilating NO. Moreover, the arginase activity in
the tracheal tissue and bronchoalveolar lavage cells of the
challenged animals was increased after the late asthmatic
reaction (Maarsingh et al. 2004).
The importance of increased arginase activity in the
pathophysiology of asthma has been confirmed in various
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antigens. Increased arginase activity in the lung was
measured after allergen challenge in BALB/c mice
sensitized to ovalbumin and to Aspergillus fumigatus
(Zimmermann et al. 2003). Notably, microarray analysis
of gene expression revealed that among the 291 common
genes that are induced by these allergens, enzymes
involved in L-arginine metabolism, particularly arginase I
and II, belong to the most predominantly overexpressed
genes. Northern blot analysis confirmed the increase in
arginase I and II gene expression; however, in contrast to
arginase I, arginase II was constitutively present, but
induced to a much lesser extent. In situ hybridization and
immunohistochemistry of ovalbumin-challenged animals
demonstrated the presence of high levels of arginase I in
the perivascular and peribronchial pockets of inflammation
in the asthmatic lung (Zimmermann et al. 2003). In line
with the results of the microarray study mentioned above,
proteomics of lung tissue from repeatedly ovalbumin-
challenged C57BL/6 mice showed a considerable upregu-
lation of arginase I (Fajardo et al. 2004).
Based on results from earlier studies in mouse macro-
phages (Corraliza et al. 1995; Modolell et al. 1995), lung
arginase activity and mRNA expression of both arginase I
and arginase II are strongly induced by the Th2 cytokines
interleukin (IL)-4 and IL-13, which are abundant in allergic
airway inflammation (Zimmermann et al. 2003). More
recently, IL-25, a novel member of the IL-17 family which
induces Th2-like airway inflammation and AHR, has also
been shown to increase arginase I mRNA expression in
mouse lung (Sharkhuu et al. 2006). Increased arginase I
gene expression was also observed in Th2-polarized—but
Fig. 2 Role of increased arginase activity in the pathophysiology of
allergic asthma. In allergic asthma, both arginase expression and
activity are increased by Th2-cytokines. Increased arginase activity
limits the bioavailability of L-arginine to constitutive nitric oxide
synthase (cNOS), leading to a reduced production of agonist-induced
nitric oxide (NO) by the airway epithelium and neuronal NO by
inhibitory nonadrenergic noncholinergic (iNANC) nerves. Under basal
conditions, NO induces airway smooth muscle relaxation by increas-
ing the production of cyclic 3′,5′ guanosine monophosphate (cGMP)
and/or by opening of calcium-activated potassium channels, thereby
attenuating the responsiveness of the airways to contractile stimuli. As
a result, arginase-induced deficiency of cNOS-derived NO in allergic
asthma contributes to airway hyperresponsiveness (AHR) in this
disease. Increased arginase activity also attenuates the availability of
L-arginine to inducible nitric oxide synthase (iNOS), which is induced
during the late asthmatic reaction or in chronic asthma. The reduced L-
arginine availability to iNOS results in the simultaneous production of
NO and the O2
− superoxide anion by the oxygenase and reductase
moieties of the enzyme, respectively, This leads to the rapid formation
of the highly reactive nitrogen species peroxynitrite (ONOO
−), which
has procontractile, proinflammatory and cytotoxic actions in the
airways. In addition, increased production of polyamines and L-
proline downstream of L-ornithine may contribute to the process of
airway remodelling. ASM Airway smooth muscle, CaM calmodulin;
e
− electron, KCa calcium-activated potassium channel, nNOS neuronal
nitric oxide synthase
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with Schistosoma mansoni eggs (Sandler et al. 2003),
supporting the importance of Th2 cytokines in inducing
arginase in asthma. Although IL-4 alone did not induce
arginase activity in human alveolar macrophages, it greatly
enhanced the response to cAMP-elevating agents (Erdely et
al. 2006). Zuyderduyn et al. (2006) recently demonstrated
that isolated human airway smooth muscle cells have a
particularly low expression of arginase II; remarkably, the
expression of arginase II, but not of arginase I, increased
after stimulation with IL-4 (Zuyderduyn et al. 2006). Of
note, in rat vascular smooth muscle cells, the expression of
arginase I was induced by IL-4 as well as by IL-13, while
arginase II was not induced by these cytokines (Wei et al.
2000).
Several studies have indicated that the transcription
factors STAT6 (Gray et al. 2005; Rutschman et al. 2001;
W e ie ta l .2000;Y a n ge ta l .2006;Z i m m e r m a n ne ta l .
2003) and CCAAT-enhancer binding protein (Gray et al.
2005) are key factors regulating the control of cytokine-
induced expression of arginase I. However, IL-4-induced
arginase II expression in the lung was hardly affected in
STAT6
−/−mice, indicating that the induction of arginase II
is largely STAT6-independent (Zimmermann et al. 2003).
Lung arginase activity and arginase I mRNA expression
were also increased in BALB/c mice challenged with
trimellitic anhydride, although the induction was lower
than in animals challenged with ovalbumin (Greene et al.
2005). In addition, lung arginase activity as well as mRNA
and protein expression of both arginase I and II have been
shown to be increased in NC/Nga mice challenged with
Dermatophagoides farinae (Takemoto et al. 2007). While
arginase I was not detected in the lung of control animals,
increased arginase I expression was observed in alveolar
macrophages and the infiltrating cells around the bron-
chioles in challenged mice (Takemoto et al. 2007). In
different mouse models of Th2 cytokine-mediated inflam-
mation in which ovalbumin (BALB/c and C57BL/6 mice),
the parasite Nippostrongylus brasiliensis (BALB/c) or the
fungus Aspergillus fumigatus (C57BL/6) was used as well
as in IL-13 overexpressing mice, gene expression in the
lung was studied to identify the genes that are commonly
expressed in lung inflammation. Among the 26 character-
istic transcripts of these five different models, arginase I
was strongly increased in all (Lewis et al. 2007). In another
study in mice, instillation of IL-13 in the airways increased
arginase activity and the expression of arginase I, but not of
arginase II, while NO synthesis was decreased (Yang et al.
2006). Interleukin-13-induced arginase expression was also
temporally correlated with the development, persistence
and resolution of IL-13-induced AHR to methacholine. In
vivo treatment with RNA interference against arginase I
abrogated the development of IL-13-induced AHR, sup-
porting the importance of increased arginase activity for
AHR in asthma (Yang et al. 2006). Further studies
demonstrating the effects of specific arginase inhibitors
and/or RNA interference against arginase I and II on
allergen-induced AHR are clearly indicated.
In addition to guinea pig and mice models of asthma,
increased arginase activity has also been observed in a rat
model of allergic asthma. Thus, arginase activity was
observed to increase in lung homogenates of rats chal-
lenged with ovalbumin for 3 consecutive days (Abe et al.
2006).
Taken together, increased arginase induction has been
observed in a wide variety of animal models of asthma,
using different species and allergens (Table 1). The
increased arginase activity may contribute to AHR by
reducing the production of bronchodilating NO as well as
by stimulating the formation of procontractile and proin-
flammatory peroxynitrite (Fig. 2). Interestingly, it was
recently demonstrated in lung epithelial cells that over-
expression of arginase may increase NF-κB activation
through a decreased production of NO, suggesting that
increased arginase activity in allergic asthma could also
promote airway inflammation and AHR by increasing the
production of inflammatory cytokines (Ckless et al. 2007).
Arginase in human asthma
The significance of increased arginase expression and
activity on the pathophysiology of human asthma was first
reported by Zimmermann et al. (2003), who demonstrated
that arginase I protein expression increases in bronchoal-
veolar lavage (BAL) cells of asthmatic patients. Moreover,
bronchial biopsies of these patients revealed enhanced
mRNA expression of arginase I in both the inflammatory
cells and in the airway epithelium. Surprisingly, elevated
levels of arginase activity were found in the serum of
asthmatic patients experiencing an exacerbation, which was
associated with reduced plasma L-arginine levels, indicating
that changes in arginase expression in asthma are not
confined to the airways and that reduced levels of
circulating L-arginine could contribute to NO deficiency
and hyperresponsiveness of the airways (Morris et al.
2004). These researchers also observed that arginase
activity declined and L-arginine concentrations increased
in some of these patients following an improvement of
symptoms (Morris et al. 2004). It is worth noting that
enhanced arginase activity in expectorated sputum of
asthmatic patients had been reported over two decades
ago (Kochanski et al. 1980).
Bergeron et al. (2007) recently published their findings
on the effect of smoking on arginase expression in human
airways. Endobronchial biopsy specimens from steroid-
naïve mild asthmatics were investigated for changes in
Naunyn-Schmiedberg’s Arch Pharmacol (2008) 378:171–184 175Table 1 Changes in arginase activity and the expression of arginase I and II in animal models and human pathology of pulmonary diseases
Clinical condition Species Condition/
stimulus
a
Localization
b Arginase
I
Arginase
II
Activity References
Asthma Human Sputum n.d. n.d. + Kochanski et al. 1980
Serum n.d. n.d. + Morris et al. 2004
BAL cells,
epithelium,
lung, MΦ
+ n.d. n.d. Zimmermann et al. 2003
Cigarette smoke Smooth
muscle,
epithelium
+ n.d. n.d. Bergeron et al. 2007
Guinea
pig
Ovalbumin BAL cells,
trachea
n.d n.d. + Maarsingh et al. 2004; Meurs
et al. 2002
Mouse Aspergillus
fumigatus
Lung + + + Lewis et al. 2007; Zimmermann
et al. 2003
Dermatophagoides
farinae
Lung, serum,
MΦ
+ + + Takemoto et al. 2007
IL-4 Lung + + n.d. Zimmermann et al. 2003
IL-13 Lung + +/= + Lewis et al. 2007; Yang et al.
2006; Zimmermann et al. 2003
Nippostrongylus
brasiliensis
Lung + = n.d. Lewis et al. 2007
Ovalbumin Lung, MΦ + + + Fajardo et al. 2004; Greene et al.
2005; Lewis et al. 2007;
Zimmermann et al. 2003
Schistosoma
mansoni eggs
Lung + n.d. n.d. Sandler et al. 2003
TMA Lung + + + Greene et al. 2005
Rat Ovalbumin Lung n.d. n.d. + Abe et al. 2006
Chronic obstructive
pulmonary disease
(COPD)
Human Sputum n.d. n.d. + Chachaj et al. 1978; Kochanski
et al. 1980
GOLD 0, I, II-A Lung = = n.d.
c Tadie et al. 2008
Rat Cigarette smoke Lung + n.d. n.d. Gebel et al. 2006
Cystic fibrosis (CF) Human Plasma,
sputum,
n.d. n.d. + Grasemann et al. 2005b; 2006b
Fibrosis Human IPF Lung – = = Kitowska et al. 2008
IPF Epithelium,
fibroblasts,
lung, MΦ
+ n.d. n.d. Mora et al. 2006
Mouse Bleomycin Epithelium,
fibroblasts,
lung, MΦ
+ + n.d. Endo et al. 2003; Kitowska et
al. 2008
Herpes virus Lung, MΦ + n.d. + Mora et al. 2006
Silica BAL cells,
lung, MΦ
+ n.d. + Misson et al. 2004
Rat Silica BAL cells,
lung
+ = + Nelin et al. 2002; Poljakovic et
al. 2007; Schapira et al. 1998
Pulmonary
hypertension (PH)
Human Primary PH PAEC, serum = + + Xu et al. 2004
Secondary PH in
sickle cell disease
Erythrocytes,
plasma,
serum
n.d. n.d. + Morris et al. 2003; 2005
Mouse Haemoglobin
−/− Lung n.d. n.d. + Hsu et al. 2007
Rat Monocrotaline PAEC n.d. n.d. + Sasaki et al. 2007
–, Decreased; +, increased; =, unchanged, n.d., not determined
aIPF, Idiopathic pulmonary fibrosis; TMA, trimilletic anhydride; IL, interleukin
bMΦ, Macrophages; PAEC, pulmonary arterial endothelial cells; BAL cells, bronchoalveolar lavage cells
cArginase inhibition decreases the sensitivity to acetylcholine in COPD patients compared to control subjects
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(ODC, the rate limiting enzyme in polyamine synthesis;
Fig. 1) and iNOS in smoking versus non-smoking patients.
Interestingly, increased immunoreactivity for arginase I and
ODC was observed in both the epithelium and smooth
muscle layers of the smokers, while iNOS-immunoreactiv-
ity was similar in both groups. In addition, arginase I
mRNA expression was increased in the epithelium and
smooth muscle bundles of smoking asthmatics as compared
to the non-smoking patients. To investigate which compo-
nent of cigarette smoke may attribute for the increase in
arginase expression, these researchers studied the effect of
nicotine on arginase and ODC expression in cultured
airway epithelial and smooth muscle cells and fibroblasts.
Nicotine significantly increased arginase I mRNA in the
epithelial cells, while a trend towards increased arginase I
mRNA expression was observed in airway smooth muscle
cells and fibroblasts after nicotine treatment. In addition,
nicotine significantly increased ODC mRNA expression in
the fibroblasts and epithelial cells, but not in the airway
smooth muscle cells (Bergeron et al. 2007). These
observations may also be of relevance for the pathogenesis
of COPD (see below).
Interestingly, single nucleotide polymorphisms (SNPs) in
arginase I and arginase II have recently been found to be
associated with atopy and the risk of childhood asthma,
respectively (Li et al. 2006).
Chronic obstructive pulmonary disease
Chronic obstructive pulmonary disease is an inflammatory
disease characterized by a progressive, irreversible decline
in lung function. The leading cause of COPD is cigarette
smoke (Pauwels et al. 2001). Smoking initiates pulmonary
inflammation characterized by the prominent infiltration of
neutrophils, macrophages and T-lymphocytes, particularly
those of the CD8
+ subset (Jeffery 2000; Sutherland and
Martin 2003). The main features of COPD are airway
hyperresponsiveness and progressive decline in lung func-
tion associated with structural changes in the peripheral
lung, including small airway remodelling that is character-
ized by mucus cell hyperplasia, airway fibrosis and
increased airway smooth muscle mass- and alveolar wall
destruction (Barnes et al. 2003; Hogg 2004; Jeffery 2000;
Postma and Kerstjens 1998; Sutherland and Martin 2003).
Based on results obtained using the single expiratory
flow technique to measure NO derived from the (predom-
inantly larger) airways, COPD has been associated with
increased levels of exhaled NO (eNO) in patients with
severe stage disease and during exacerbations (Agusti et al.
1999; Bhowmik et al. 2005; Maziak et al. 1998). However,
this method has also shown that eNO is often low or in the
normal range in patients with stable COPD (Kharitonov and
Barnes 2001), a state that has been attributed to the effect of
tobacco smoking, which downregulates eNOS (Hutchison
et al. 2001) and iNOS (Hoyt et al. 2003). Indeed, smokers
exhale lower amounts of NO than nonsmokers (Kharitonov
et al. 1995b). Reduced levels of NO may also result from
smoking-induced increased oxidative stress through the
formation of peroxynitrite from NO and superoxide anions.
In support of this hypothesis, peroxynitrite generation has
been found to be considerably increased in sputum macro-
phages of COPD patients, which is negatively correlated
with forced expiratory volume in the first second (FEV1)i n
these patients (Achenes et al. 2000). Measurements of eNO
taken at multiple respiratory flows have indicated that,
while airway NO is relatively low in COPD, there is an
increase in alveolar NO that is related to disease severity
and not affected by smoking (Brindicci et al. 2005).
Quite interestingly, microarray analysis of gene expres-
sion followed by reverse transcription real-time quantitative
PCR in lungs from smoking rats revealed a marked time-
and dose-dependent upregulation of arginase I expression
during 2–13 weeks of smoke exposure (2 × 1 h/day, 5 days/
week; Gebel et al. 2006). Smoke-induced expression of
arginase I may be involved in the relatively low NO
production in the airways of COPD patients as well as in
the peroxynitrite production and AHR found in these
patients. The latter development is supported by the recent
observation that increased arginase activity may be
involved in the enhanced sensitivity to methacholine
shown by bronchial preparations from patients with mild
COPD (Tadie et al. 2008). Interestingly, subcutaneous
injection (5 weeks, once daily) of cigarette smoke extract
in rabbits increased the expression of arginase I and
increased arginase activity in cavernous tissue, while NOS
activity and nNOS expression were significantly decreased
(Imamura et al. 2007). Moreover, electric field stimulation-
induced neurogenic and NO-mediated cavernous smooth
muscle relaxation was attenuated by cigarette smoke extract
administration (Imamura et al. 2007). Whether cigarette
smoke-induced increase in arginase activity in the airways
also leads to reduced iNANC-mediated NO production and
airway smooth muscle relaxation has yet to be studied.
As already mentioned, nicotine, a major constituent of
tobacco smoke, may upregulate arginase I in airway
structural cells (Bergeron et al. 2007). Interestingly, recent
evidence suggests that human neutrophils constitutively
express high levels of arginase I in azurophilic granules
(Munder et al. 2005) which, like other constituents of these
granules, including neutrophil elastase, may be liberated in
patients with COPD (Renkema et al. 1991). Since neutro-
phil abundance is also demonstrated in patients with severe
asthma as well as in those with cystic fibrosis, neutrophil
arginase could also be involved in the pathogenesis of these
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diseases remains to be established. Remarkably, as with
asthma, increased arginase activity in the sputum of COPD
patients had already been found as early as the late 1970s
(Chachaj et al. 1978; Kochanski et al. 1980).
Cystic fibrosis
Cystic fibrosis is a progressive disease, characterized by
pulmonary inflammation and bacterial infection, chronic
airway obstruction, airway remodelling and AHR (Hays et
al. 2005; Hilliard et al. 2007; Tiddens and De Jong 2007).
Despite the inflammatory nature of CF, this disease is
characterized by decreased levels of eNO (Elphick et al.
2001; Grasemann et al. 1997), and reduced NO levels in the
airways of CF patients may contribute to microbial
infection and colonization as well as to functional changes
of the airways. Several mechanisms may contribute to the
low pulmonary levels of NO in CF, including a reduced
expression of iNOS (Downey and Elborn 2000), poly-
morphisms of nNOS (Grasemann et al. 2000, 2002) and
eNOS (Grasemann et al. 2003), mechanical retention of NO
in airway secretions (Grasemann et al. 1998), increased
metabolism to peroxynitrite (Robbins et al. 2000), con-
sumption of NO by denitrifying bacteria (Gaston et al.
2002) and increased arginase activity in the airways
(Grasemann et al. 2005b, 2006b).
In a mouse model of CF, an impaired electrical field
stimulation-induced airway smooth muscle relaxation was
found, which was reversed by L-arginine and NO (Mhanna
et al. 2001). This result indicates that a deficiency of NO
due to substrate limitation to nNOS compromises airway
relaxation and contributes to airway obstruction. In support
of this mechanism, a positive correlation has been found
between pulmonary function and exhaled NO and NO
metabolite concentrations in the sputum of CF patients
(Grasemann et al. 1997, 1998). Moreover, inhalation of L-
arginine increased exhaled NO levels and improved lung
function in these patients (Grasemann et al. 2006a).
However, oral L-arginine treatment increased L-arginine
levels in sputum and plasma as well as levels of exhaled
NO, but failed to improve pulmonary function (Grasemann
et al. 2005a). Increased consumption by arginase may
account for the L-arginine limitation in CF, since sputum
arginase activity in CF is markedly increased in comparison
to controls and is even further increased during pulmonary
exacerbation (Grasemann et al. 2005b). Interestingly,
increased arginase activity was found to be negatively
correlated with lung function (FEW1), while increased eNO
and improved lung function due to antibiotic treatment
were associated with a decrease in arginase activity
(Grasemann et al. 2005b). At least some portion of the
increased arginase activity in the above-mentioned study
could have been derived from microorganisms in the
sputum. However, increased arginase activity was also
observed in plasma of CF patients during pulmonary
exacerbation, while plasma L-arginine levels were de-
creased (Grasemann et al. 2006b). Treatment with anti-
biotics decreased the arginase activity and restored the
L-arginine levels in these patients, thereby confirming the
close relationship between increased arginase activity and
decreased levels of L-arginine (Grasemann et al. 2006b).
Taken together, these findings indicate that increased
arginase activity in CF contributes to the NO deficiency
and pulmonary obstruction in CF by limiting the availabil-
ity of L-arginine to NOS.
Arginase in airway remodelling and fibrotic pulmonary
disorders
Increased arginase activity in asthma, COPD and cystic
fibrosis may also contribute to the airway remodelling
observed in these diseases through the increased production
of L-proline and the polyamines putrescine, spermidine and
spermine from L-ornithine (Fig. 1, 2). L-Proline, the
precursor of collagen, is synthesized from L-ornithine in a
two-step reaction involving ornithine aminotransferase and
pyrroline-5-carboxylate reductase, while ODC initiates the
synthesis of polyamines that could be involved in the
proliferation of structural cells in the airways (Hoet and
Nemery 2000; Meurs et al. 2003; Ricciardolo et al. 2005;
Wu and Morris 1998; Fig. 1). In support of this concept,
transfection of rat vascular smooth muscle cells with
arginase I induced increased polyamine levels and en-
hanced proliferation of these cells (Wei et al. 2001). The
involvement of arginase in airway remodelling remains to
be established, however. In support of a potential role of
arginase in airway fibrosis in asthma, IL-4 and IL-13
increased arginase I and II expression and arginase activity
in cultured rat fibroblasts (Lindemann and Racke 2003),
a n dI L - 4i n d u c e di n c r e a s e da r g i n a s eI Ie x p r e s s i o ni n
human airway smooth muscle cells (Zuyderduyn et al.
2006). In addition, increased levels of polyamines have
been observed in the mouse lung after allergen challenge
(Zimmermann et al. 2003) and in the serum of asthmatic
patients (Kurosawa et al. 1992), respectively. Notably,
growth factors, such as epidermal growth factor (EGF)
and platelet-derived growth factor (PDGF), which are
known to be enhanced in asthma, may be involved in the
induction of arginase and of enzymes participating in the
polyamine synthetic pathway (Nelin et al. 2005; Thyberg
and Fredholm 1987a, b). Polyamines can stimulate the
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promoting histone acetyltransferase activity, resulting in
chromatin hyperacetylation (Hobbs and Gilmour 2000).
The activity of histone acetyltransferase was found to be
increased in bronchial biopsies of asthmatic patients (Ito et
al. 2002).
As mentioned above, exposure to cigarette smoke and/or
nicotine may induce increased expression of arginase I and
ODC in human airway structural cells (Bergeron et al.
2007). The results of a study showing that long-term
exposure to mainstream smoke increased ODC activity in
rat trachea and lung provides experimental support for this
possibility (Olson 1985). That nicotine could account for
the effect of cigarette smoke was shown by the observation
that a single subcutaneous injection of nicotine also induced
a transient increase in ODC activity in rat trachea (Olson
and Crooks 1985). These findings suggest that smoking
may contribute to airway remodelling in asthma as well as
in COPD.
Expression of collagen I mRNA and arginase I and II
mRNA and protein was increased in bleomycin-induced
lung fibrosis in mice (Endo et al. 2003). Arginase II
expression co-localized with the collagen-specific chaperone
Hsp47, indicating a prominent role for arginase in collagen
synthesis in lung fibrosis (Endo et al. 2003). In another
study, Kitowska et al. (2008) observed a bleomycin-induced
time-dependent increase in arginase I and II expression in
mouse lung that was accompanied by decreased levels of
L-arginine; arginase was localized to macrophages and
epithelial cells as well as in interstitial fibroblasts, especially
in fibrotic lesions. Increased arginase expression in fibrotic
areas was also observed in herpes virus-induced lung
fibrosis in mice (Mora et al. 2006). Interestingly, arginase I
and II expression was induced by transforming growth
factor (TGF)-β in primary mouse fibroblasts, and treatment
with the non-specific arginase inhibitor NOHA prevented
the TGF-β-induced increase in collagen content in a post-
transcriptional manner (Kitowska et al. 2008). In several
animal models of silicosis, another inflammatory lung
disease characterized by fibrosis, arginase activity and
arginase I expression were also enhanced in lung and
alveolar macrophages (Misson et al. 2004; Nelin et al. 2002;
Poljakovic et al. 2007; Schapira et al. 1998). However, a
direct relationship between increased arginase activity and
expression and fibrosis has not always been found: Misson
et al. (2004) reported that arginase I expression and activity
in lung of silica-exposed mice were increased at 3 days, but
not 30 or 60 days, following silica exposure, while levels of
hydroxyproline – a marker of fibrosis – were increased at all
three time points. A study involving treatment with an
arginase inhibitor could clarify whether (increased) arginase
activity is indeed involved in silica-induced fibrosis.
In line with the above findings in mouse models of lung
fibrosis, arginase I expression was found to be increased in
patients with idiopathic pulmonary fibrosis (IPF), especially
in the alveolar macrophages, epithelial cells and areas with
pleura thickening and interstitial fibrosis (Mora et al. 2006).
However, in another study on IPF patients, lung arginase I
expression was decreased, while no differences were
observed in arginase II expression and arginase activity in
the lung, nor in arginase I and II expression in cultured
fibroblasts from these patients (Kitowska et al. 2008).
Therefore, further investigation is needed to establish the
role of arginase in human pulmonary fibrotic disease.
Arginase and pulmonary hypertension
Reduced levels of NO have been observed in lungs of
patients with pulmonary hypertension (PH; Kaneko et al.
1998). These reduced NO levels may be caused by changes
in L-arginine metabolism, since low levels of plasma L-
arginine have been found in patients with primary and
secondary forms of hypertension (Morris et al. 2003, 2005;
Xu et al. 2004). Inhalation of NO as well as L-arginine
supplementation have shown to be of potential benefit in
the treatment of PH (Atz and Wessel 1997; Morris et al.
2003, 2005). The decreased L-arginine levels may result
from increased arginase activity, and increased arginase
activity in serum has been detected in patients with primary
PH (PPH), which was associated with reduced L-arginine to
L-ornithine levels in these patients (Xu et al. 2004).
Moreover, increased arginase II expression has been
observed in PPH patients, especially in the endothelium of
arteries and arterioles, as well as in cultured pulmonary
arterial endothelial cells from these patients (Xu et al.
2004). Increased arginase activity was also observed in a
mouse model of PH: in mice with monocrotaline-induced
PH, arginase activity was increased, while NOS activity
and cGMP production were reduced (Sasaki et al. 2007). Of
note, reduced eNOS expression and increased accumulation
of endogenous NOS inhibitors, such as monomethylargi-
nine and asymmetric dimethylarginine, also contributed to
reduced NO production in this model (Sasaki et al. 2007).
Decreased plasma levels of L-arginine and NO metabo-
lites have also been observed in infants with persistent PH
(Pearson et al. 2001); however, whether this is caused by
increased arginase activity is presently unknown. Interest-
ingly, a recent study indicated that arginase II expression in
pulmonary arteries is regulated developmentally, with
maximal expression and activity during fetal life (Belik et
al. 2008). It is therefore tempting to speculate that
developmentally high levels of arginase activity may be
involved in the pathogenesis of PPH of the newborn.
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and plasma arginase activity have also been observed in
patients with sickle cell anemia and associated secondary PH
(Morris et al. 2003, 2005). Oral treatment with L-arginine
was found to increase the plasma levels of both L-arginine
and L-ornithine and to reduce pulmonary artery systolic
pressure (Morris et al. 2003). The primary cause of the
increased plasma arginase activity in patients with sickle cell
anemia and PH may be the release of the enzyme from
erythrocytes during intravascular haemolysis. Haemolysis
may also contribute to reduced NO bioavailability and
endothelial dysfunction via the release of erythrocyte
haemoglobulin, which scavenges NO (Morris et al. 2005).
Increased arginase activity in the lung and in plasma and
reduced eNOS activity in the lung were observed in a mouse
model of sickle cell disease and PH (Hsu et al. 2007). Similar
pathobiology was observed in a nonsickle mouse model of
acute alloimmune haemolysis, indicating that haemolysis is
sufficient to cause these changes (Hsu et al. 2007).
In conclusion, increased arginase activity appears to be a
major factor in the pathophysiology of both primary and
secondary PH through its action of limiting the bioavail-
ability of L-arginine to eNOS in the pulmonary vasculature.
Conclusions
It is a well-established fact that changes in L-arginine
metabolism mediated by NO synthases are involved in a
variety of diseases, including diseases of the respiratory
system. During the last few years, the potential role of
arginases in these diseases as key regulators of the synthesis
of NO and of polyamines and L-proline has been attracting
increasing interest. Results from animal model studies have
indicated that arginase is a key factor in the regulation of
airway responsiveness, and pharmacological studies using
specific arginase inhibitors have revealed that this enzyme
has a pathophysiological role in the pathogenesis of allergic
asthma. Moreover, remarkable increases in pulmonary
arginase activity and/or expression associated with altered
NO and L-arginine homeostasis have been observed in
animal models and human pathology of asthma, COPD,
cystic fibrosis, idiopathic pulmonary fibrosis and pulmo-
nary hypertension. Although the functional role of arginase
overexpression in most of these diseases has not yet fully
been established, there is accumulating evidence that
arginase may be an important novel target for drug therapy
of these diseases.
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